MutantDx is focused on out-licensing a portfolio of twelve patented platform technologies in molecular diagnostics that will revolutionize cancer diagnosis and treatment. They offer the most clinically reliable detection and verification of actionable DNA cancer markers (mutations) available today.

Our technologies meet currently unsatisfied clinical need with substantial competitive advantages over alternative methodologies, and are supported by extensive publications.

Applications include the identification and confirmation of DNA cancer mutations in the Liquid Biopsy as well as tumor biopsies.

Mutant Dx technologies are now available for licensing by companies that have the capability to capture the rapidly expanding global market in cancer diagnostics.

Dr Roger Hodkinson


MutantDx Inc.

17204 106A Avenue
Edmonton, Alberta
Canada T5S 1E6